Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS

Raymond James analyst Christopher Raymond has maintained their bullish stance on ALMS stock, giving a Buy rating today.

Christopher Raymond has given his Buy rating due to a combination of factors centered on envu’s strong showing at the AAD meeting, where Phase 3 data underscored efficacy that matches or closely tracks both Takeda’s zasocitinib and J&J’s icotrokinra on key psoriasis endpoints. He views the drug’s performance on more stringent Week 24 measures such as PASI-90 and PASI-100 as sufficiently robust to position envu as a credible competitor within the expanding oral psoriasis treatment landscape.

At the same time, he highlights safety as a key differentiator, noting that envu demonstrated lower rates of overall and serious adverse events, fewer infections like upper respiratory tract issues, and no meaningful lab or TB signals that might necessitate frequent monitoring. In contrast, zasocitinib showed higher rates of side effects and raised questions around malignancy signals, which Raymond believes could dampen physician and regulatory enthusiasm for that rival. Taken together, he concludes that envu’s competitive efficacy, cleaner safety profile, and resulting commercial positioning justify a Buy recommendation on ALMS shares.

In another report released today, Chardan Capital also maintained a Buy rating on the stock with a $38.00 price target.